| Q1 2026 (Q1 2025) | ||
| Revenue was SEK 4.6 M (9.8 M) | Cash and cash equivalent SEK 532.0 M (260.7) | |
| Operating profit/loss was SEK -56.5 M (-16.5 M) | Basic earnings/loss per share was SEK -0.33 (0.17) | |
| Net profit/loss was SEK -46.2 M (19.0 M) | Diluted earnings/loss per share were SEK -0.33 (0.16) | |
Comments from the CEO
“In the first quarter of 2026, we continued disciplined execution of our partnership-driven strategy. With three proprietary programs supported by GLP toxicology material, we are preparing to enter the clinic. Our partnered assets offer near-term milestone potential, while our internal pipeline advances toward key value inflection points. Engagement with international investment and pharmaceutical communities is strengthening. We remain focused on operating partly self-financed through partnerships, while maintaining strategic flexibility for future growth. Saniona is positioned for the next phase of clinical and shareholder value creation.”
Investor call
Saniona will host a Q1 investor call on 26 May 2026, at 11.00 CEST.
At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.
Access to the event can be obtained through the following link:
https://www.redeye.se/events/1143627/live-q-saniona-5
REPLAY access
Webcast replay will be available at www.saniona.com and at www.redeye.se